EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma
EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma
复制标题
EZH2 是一种负面预后因素，在胶质母细胞瘤中表现出促癌活性。
DOI：
10.1016/j.canlet.2014.11.003
复制
发表时间：
2015-01-28
期刊：
影响因子：
9.7
通讯作者：
Kang, Chunsheng
中科院分区：
文献类型：
--
作者：
Zhang, Junxia;Chen, Luyue;Kang, Chunsheng
基于mRNA表达的单个或更少基因的鉴定作为胶质母细胞瘤（GBM）的临床诊断标志物仍然是一个挑战。最近的数据显示了EZH 2在几种人类癌症中的潜在致癌作用和预后意义。然而，EZH 2在胶质瘤发生中的临床特征和进一步机制仍然知之甚少。在这项研究中，我们发现EZH 2表达增加与肿瘤分级相关。GBM中EZH 2的高表达被确定为短总生存期的强而独立的预测因子。此外，我们筛选了GBM中的EZH 2靶标和相关基因。EZH 2的抑制诱导细胞周期停滞并抑制体内肿瘤生长。该事件代表β-连环蛋白/TCF 4和STAT 3信号传导的正反馈回路。因此，EZH 2可能是GBM的独立预后因子和潜在治疗靶点。(C)由Elsevier爱尔兰Ltd.出版
The identification of single or less genes based on mRNA expression as clinical diagnostic markers for glioblastoma (GBM) remains a challenge. Recent data have shown the potential oncogenic role and prognostic significance of EZH2 in several human cancers. However, the clinical signature and further mechanisms of EZH2 function in gliomagenesis are still poorly understood. In this study, we found that increased EZH2 expression was associated with tumor grade. High expression of EZH2 in GBM was determined to be a strong and independent predictor of short overall survival. Further, we screened EZH2 targets and associated genes in GBM. Repression of EZH2 induced cell cycle arrest and inhibited tumor growth in vivo. This event represents a positive feedback loop with beta-catenin/TCF4 and STAT3 signaling. Taken together, EZH2 could be an independent prognostic factor and potential therapeutic target for GBM. (C) 2014 Published by Elsevier Ireland Ltd.